.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a median consequence of 11 months, people along with metastatic stomach lumps that received biomarker-matched therapies based on spreading cyst DNA profiling presented a better clinical advantage than those receiving unmatched therapy.